IDO-Expressing Fibroblasts Protect Islet Beta Cells From Immunological Attack and Reverse Hyperglycemia in Non-Obese Diabetic Mice

Journal of Cellular Physiology

Volumn 231, Issue 9, 2016, Pages 1964-1973

  Zhang, Yun ^a   Jalili, Reza B ^a   Kilani, Ruhangiz T ^a   Elizei, Sanam Salimi ^a   Farrokhi, Ali ^a   Khosravi Maharlooei, Mohsen ^a   Warnock, Garth L ^a   Ao, Ziliang ^a   Marzban, Lucy ^a   Ghahary, Aziz ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GLUCOSE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; KYNURENINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FIBROBLAST; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; ANIMAL; C57BL MOUSE; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; NONOBESE DIABETIC MOUSE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; FIBROBLASTS; HYPERGLYCEMIA; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INSULIN-SECRETING CELLS; MALE; MICE, INBRED C57BL; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY;

EID: 84966378314     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25301     Document Type: Article

References (50)

1. Abdul-Rasoul M, Habib H, Al-Khouly M. 2006. The honeymoon phase' in children with type 1 diabetes mellitus: Frequency, duration, and influential factors. Pediatr Diabetes 7:101-107.
2. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T, Herold KC. 2012. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: Evidence of improved immune regulation. Diabetes 61:145-154.
3. Akirav E, Kushner JA, Herold KC. 2008. Beta-cell mass and type 1 diabetes: Going, going, gone? Diabetes 57:2883-2888.
4. Chan LS, Hammerberg C, Kang K, Sabb P, Tavakkol A, Cooper KD. 1992. Human dermal fibroblast interleukin-1 receptor antagonist (IL-1ra) and interleukin-1 beta (IL-1 beta) mRNA and protein are co-stimulated by phorbol ester: Implication for a homeostatic mechanism. J Invest Dermatol 99:315-322.
5. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. 2008. The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181:5396-5404.
6. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. 2005. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 202:1387-1397.
7. Curran TA, Jalili RB, Farrokhi A, Ghahary A. 2014. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells. Immunobiology 219:17-24.
8. Dahal LN, Hall LS, Barker RN, Ward FJ. 2013. Indoleamine 2, 3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia. Clin Exp Immunol 173:58-66.
9. Fallarino F, Grohmann U. 2011. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem 18:2215-2221.
10. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752-6761.
11. Fallarino F, Luca G, Calvitti M, Mancuso F, Nastruzzi C, Fioretti MC, Grohmann U, Becchetti E, Burgevin A, Kratzer R, van Endert P, Boon L, Puccetti P, Calafiore R. 2009. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med 206:2511-2526.
12. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, Nano R, Olek S, Maffi P, Scavini M, Secchi A, Staudacher C, Bonifacio E, Battaglia M. 2011. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60:2903-2913.
13. Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, Robbins PD. 1999. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 48:1730-1736.
14. Graser RT, DiLorenzo TP, Wang F, Christianson GJ, Chapman HD, Roopenian DC, Nathenson SG, Serreze DV. 2000. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol 164:3913-3918.
15. Gregori S, Giarratana N, Smiroldo S, Adorini L. 2003. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 171:4040-4047.
16. Grishman EK, White PC, Savani RC. 2012. Toll-like receptors, the NLRP3 inflammasome, and interleukin-1beta in the development and progression of type 1 diabetes. Pediatr Res 71:626-632.
17. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P. 2003. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 198:153-160.
18. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, Knip M, Otonkoski T, Vaarala O. 2010. IL-17 immunity in human type 1 diabetes. J Immunol 185:1959-1967.
19. Hosseini-Tabatabaei A, Jalili RB, Khosravi-Maharlooei M, Hartwell R, Kilani RT, Zhang Y, Ghahary A. 2015. Immunoprotection and functional improvement of allogeneic islets in diabetic mice, using a stable indoleamine 2, 3-dioxygenase producing scaffold. Transplantation 99:1341-1348.
20. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. 2000. Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596-3599.
21. Jalili RB, Forouzandeh F, Rezakhanlou AM, Hartwell R, Medina A, Warnock GL, Larijani B, Ghahary A. 2010. Local expression of indoleamine 2, 3 dioxygenase in syngeneic fibroblasts significantly prolongs survival of an engineered three-dimensional islet allograft. Diabetes 59:2219-2227.
22. Jalili RB, Moeen Rezakhanlou A, Hosseini-Tabatabaei A, Ao Z, Warnock GL, Ghahary A. 2011. Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal. J Cell Physiol 226:1813-1819.
23. Jalili RB, Rayat GR, Rajotte RV, Ghahary A. 2007. Suppression of islet allogeneic immune response by indoleamine 2, 3 dioxygenase-expressing fibroblasts. J Cell Physiol 213:137-143.
24. Kanangat S, Postlethwaite AE, Higgins GC, Hasty KA. 2006. Novel functions of intracellular IL-1ra in human dermal fibroblasts: Implications in the pathogenesis of fibrosis. J Invest Dermatol 126:756-765.
25. Katz J, Benoist C, Mathis D. 1993. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 23:3358-3360.
26. Kudo Y. 2013. The role of placental indoleamine 2, 3-dioxygenase in human pregnancy. Obstet Gynecol Sci 56:209-216.
27. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Investig 109:131-140.
28. Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kuhlcke K, Ohashi PS, Hengartner H, Zinkernagel RM. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343-1347.
29. Lehuen A, Diana J, Zaccone P, Cooke A. 2010. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 10:501-513.
30. Luan X, Lu Q, Jiang Y, Zhang S, Wang Q, Yuan H, Zhao W, Wang J, Wang X. 2012. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol 189:245-252.
31. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N. 2008. HIV- activated human plasmacytoid DCs induce Tregs through an indoleamine 2, 3-dioxygenase-dependent mechanism. J Clin Invest 118:3431-3439.
32. Maret M, Chicheportiche R, Dayer JM, Gabay C. 2004. Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: Phenotypic differences between human dermal and synovial fibroblasts. Cytokine 25:193-203.
33. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. 2009. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 39:216-224.
34. Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, Xu L, Priatel JJ, Levings MK, Tan R. 2010. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 185:3814-3818.
35. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler AG, Boehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T. 2013. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381:1905-1915.
36. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22:633-642.
37. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193.
38. Pagni PP, Bresson D, Rodriguez-Calvo T, Bel Hani A, Manenkova Y, Amirian N, Blaszczak A, Faton S, Sachithanantham S, von Herrath MG. 2014. Combination therapy with an anti- IL-1beta antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes 63:2015-2025.
39. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U. 2011. Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12:870-878.
40. Poormasjedi-Meibod MS, Jalili RB, Hosseini-Tabatabaei A, Hartwell R, Ghahary A. 2013. Immuno-regulatory function of indoleamine 2, 3 dioxygenase through modulation of innate immune responses. PloS ONE 8:e71044.
41. Rezakhanlou AM, Habibi D, Lai A, Jalili RB, Ong CJ, Ghahary A. 2010. Highly efficient stable expression of indoleamine 2, 3 dioxygenase gene in primary fibroblasts. Biol Proced Online 12:9028.
42. Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti MC, Grohmann U, Segal BH, Puccetti P. 2008. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451:211-215.
43. Schwarznau A, Hanson MS, Sperger JM, Schram BR, Danobeitia JS, Greenwood KK, Vijayan A, Fernandez LA. 2009. IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. J Cell Physiol 220:341-347.
44. Soleimanpour SA, Stoffers DA. 2013. The pancreatic beta cell and type 1 diabetes: Innocent bystander or active participant? Trends Endocrinol Metab 24:324-331.
45. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor Straten P, Andersen MH. 2011. Indoleamine 2, 3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117:2200-2210.
46. Suarez-Fuentetaja N, Domenech-Garcia N, Paniagua-Martin MJ, Marzoa-Rivas R, Barge-Caballero E, Grille-Cancela Z, Pombo-Otero J, Muniz-Garcia J, Castro-Beiras A, Crespo-Leiro MG. 2012. Indoleamine, 2-3 dioxygenase activity could be an early marker of graft rejection in heart transplantation. Transplant Proc 44:2645-2648.
47. Taylor MW, Feng GS. 1991. Relationship between interferon-gamma, indoleamine 2, 3- dioxygenase, and tryptophan catabolism. FASEB J 5:2516-2522.
48. Vudattu NK, Herold KC. 2014. Treatment of new onset type 1 diabetes with teplizumab: Successes and pitfalls in development. Expert Opin Biol Ther 14:377-385.
49. Wang Z, Xiao L, Shi BY, Qian YY, Bai HW, Chang JY, Cai M. 2008. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation. Transplant Immunol 19:69-73.
50. Yan Y, Zhang GX, Gran B, Fallarino F, Yu S, Li H, Cullimore ML, Rostami A, Xu H. 2010. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 185:5953-5961.